Key pipeline drugs such as Gliatilin (supports brain health), Januvia (diabetes drug), Telminuvo (antihypertensive) are on the firm growth track. We expect to see solid earnings growth in 2018. - Prescriptions for drugs licensed in from global pharmas as well as its incrementally modified drugs (IMDs) and generics are growing faster than the market average. We maintain BUY and our target price of KRW170,000.
Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.